[1] Teo SK.Properties of thalidomide and its analogues:implications for anticancer therapy[J].AAPS J,2005,7(1):14-19.
[2] Cao WY.Pharmacology and clinical use of Lenalidomide[J].Qilu Pharmaceutical Affairs(齐鲁药事),2008,27(4):229-231.
[3] Li JW,Sun XR,Zhang XL,et al.Efficacy and adverse effect of lenalidomide plus rituximab in mantle cell lymphoma patients:a meta-analysis[J].Clin Med J (临床药物治疗杂志),2018,16(5):64-69.
[4] Li M,Xue W,Li CX,et al.Adverse reactions of lenalidomide and their prevention and management[J].Chin J New Drug(中国新药杂志),2013,22(19):2332-2335.
[5] Huang ZP,Liu CY.Analysis on adverse drug reactions of lenalidomide[J].Chin J Clin Pharmacol(中国临床药理学杂志),2014,30(10):952-954.
[6] CFDA.Provisions for Adverse Drug Reaction Reporting and Monitoring(药品不良反应报告和监测管理办法)[EB/OL].(2011-05-04)[2017-02-15] http://www.sda.gov.cn/WS01/CL0053/62621_7.html.
[7] Du JB,Zhang CY.Prevention and treatment of drug-induced myocardial damage[J].J Appl Clin Pediatr (实用儿科临床杂志),2010,25(1):1-5.